About

Commonwealth Diagnostics International, Inc. (CDI) is an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose common sources of digestive distress and functional gastrointestinal ailments. Focused on our patient-centric principles, our cost-effective portfolio of diagnostic products results in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system. Our expansive portfolio includes non-invasive at-home breath testing kits for Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methane Overgrowth (IMO), and carbohydrate malabsorption disorders, as well as IBSchekĀ®, a proprietary capillary collection test for Irritable Bowel Syndrome (IBS-D/M), and MyGIHealth, a cloud-based platform that enables patients to monitor, manage and understand their GI-related symptoms. Operating out of our CLIA-certified laboratory, and as an FDA registered, ISO 13485 certified medical device manufacturer, we pride ourselves on our partnerships with industry-leading health systems, hospitals, and private practices worldwide. For more information, visit commdx.com.